Back to News
Market Impact: 0.3
ADC Therapeutics Reports Strong Lymphoma Responses, Plans Phase III Study
Source: marketbeat.com
Healthcare & BiotechCorporate EarningsCompany FundamentalsCorporate Guidance & Outlook
ADC Therapeutics reported preliminary third-quarter ZYNLONTA sales of approximately $21 million and expects its cash runway to extend into 2029. The company also outlined new lymphoma data and plans for further studies of the cancer drug; no sales comparison or study results were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ADCT0.35
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Voters rebuff data centers in every ballot measure except one during the 2026 midterms
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Nifty Bounces Back to Beat All of Asia on Foreign Flows, Earnings
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper
- Quartr Alternatives for Institutional Research Teams